[1]World Health Organization: WHO (1972).
Definitions.
http:
//www.who.int/medicines/areas/quality_safety/
safety_efficacy/trainingcourses/definitions.pdf
(10 Sep 2019, date last accessed).
[2]Poudel, D. R., Acharya, P., Ghimire, S., et al. (2017). Burden of
hospitalizations related to adverse drug events in the usa: a retrospective
analysis from large inpatient database. Pharmacoepidemiology and drug
safety, 26(6), 635–641.
[3]Weiss, A., Elixhauser, A., Bae, J., et al. (2013). Origin of adverse drug
events in us hospitals, 2011. HCUP Statistical Brief , 158.
[4]Hoots, B. E., Xu, L., Kariisa, M., et al. (2018). 2018 annual surveillance
report of drug-related risks and outcomes–united states. CDC National
Center for Injury Prevention and Control.
[5]Rieder, M. J. (1994). Mechanisms of unpredictable adverse drug
reactions. Drug Safety, 11(3), 196–212.
[6]Mann, R. D. and Andrews, E. B. (2007). Pharmacovigilance. John
Wiley & Sons.
[7]Poloju, N. and Muniganti, P. (2018). Adverse drug reaction detection
using data mining approaches: A survey. Internatinal journal of recent
trends in engineering and research, 2018.
[8]Chen, Y. G., Wang, Y. Y., and Zhao, X. M. (2016). A survey on
computational approaches to predicting adverse drug reactions. Current
topics in medicinal chemistry, 16(30), 3629–3635.
[9]Ho, T. B., Le, L., Thai, D. T., et al. (2016). Data-driven approach
to detect and predict adverse drug reactions. Current pharmaceutical
design, 22(23), 3498–3526.
[10]Wang, X., Thijssen, B., and Yu, H. (2013). Target essentiality and
centrality characterize drug side effects. PLoS computational biology,
9(7), e1003119.
[11]Alberti, P. and Cavaletti, G. (2014). Management of side effects
in the personalized medicine era: chemotherapy-induced peripheral
neuropathy. In Pharmacogenomics in Drug Discovery and Development,
pages 301–322. Springer.
[12]Bao, Y., Kuang, Z., Peissig, P., et al. (2017). Hawkes process
modeling of adverse drug reactions with longitudinal observational data.
In Machine learning for healthcare conference, volume 2017, pages
177–190. Proceedings of Machine Learning Research.
[13]U.S. Food and Drug Administration (2019).
Questions and
answers on fda’s adverse event reporting system (faers).
https://www.fda.gov/drugs/surveillance/
fda-adverse-event-reporting-system-faers, 10 Sep
2019, date last accessed.
[14]Stang, P. E., Ryan, P. B., Racoosin, J. A., et al. (2010). Advancing the
science for active surveillance: rationale and design for the observational
medical outcomes partnership. Annals of internal medicine, 153(9),
600–606.
[15]Hripcsak, G., Duke, J. D., Shah, N. H., et al. (2015).
Observational health data sciences and informatics (ohdsi): opportunities
for observational researchers.
Studies in health technology and
informatics, 216, 574.
[16]Kuhn, M., Letunic, I., Jensen, L. J., et al. (2015). The sider database of
drugs and side effects. Nucleic acids research, 44(D1), D1075–D1079.
A Self-archived copy in
Kyoto University Research Information Repository
https://repository.kulib.kyoto-u.ac.jp
“main” — 2019/11/18 — 13:41 — page 11 — #11
A survey on ADR
[17]Liu, M., Wu, Y., Chen, Y., et al. (2012). Large-scale prediction
of adverse drug reactions using chemical, biological, and phenotypic
properties of drugs. Journal of the American Medical Informatics
Association, 19(e1), e28–e35.
[18]Banda, J. M., Evans, L., Vanguri, R. S., et al. (2016). A curated
and standardized adverse drug event resource to accelerate drug safety
research. Scientific data, 3, 160026.
[19]Tatonetti, N. P., Patrick, P. Y., Daneshjou, R., and Altman, R. B.
(2012). Data-driven prediction of drug effects and interactions. Science
translational medicine, 4(125), 125ra31–125ra31.
[20]Wishart, D. S., Knox, C., Guo, A. C., et al. (2007). Drugbank: a
knowledgebase for drugs, drug actions and drug targets. Nucleic acids
research, 36(suppl_1), D901–D906.
[21]Kim, S., Thiessen, P. A., Bolton, E. E., et al. (2015). Pubchem
substance and compound databases. Nucleic acids research, 44(D1),
D1202–D1213.
[22]Berman, H. M., Westbrook, J., Feng, Z., et al. (2000). The protein
data bank. Nucleic acids research, 28(1), 235–242.
[23]Liu, T., Lin, Y., Wen, X., et al. (2006). Bindingdb: a web-accessible
database of experimentally determined protein–ligand binding affinities.
Nucleic acids research, 35(suppl_1), D198–D201.
[24]Keshava Prasad, T., Goel, R., Kandasamy, K., et al. (2008). Human
protein reference database⣔2009 update. Nucleic acids research,
37(suppl_1), D767–D772.
[25]Davis, A. P., Murphy, C. G., Saraceni-Richards, C. A., et al. (2008).
Comparative toxicogenomics database: a knowledgebase and discovery
tool for chemical–gene–disease networks. Nucleic acids research,
37(suppl_1), D786–D792.
[26]Kanehisa, M. and Goto, S. (2000). Kegg: kyoto encyclopedia of genes
and genomes. Nucleic acids research, 28(1), 27–30.
[27]Günther, S., Kuhn, M., Dunkel, M., et al. (2007). Supertarget and
matador: resources for exploring drug-target relationships. Nucleic acids
research, 36(suppl_1), D919–D922.
[28]Cai, M.-C., Xu, Q., Pan, Y.-J., et al. (2014). Adrecs: an ontology
database for aiding standardization and hierarchical classification of
adverse drug reaction terms. Nucleic acids research, 43(D1), D907–
D913.
[29]Ji, Z. L., Han, L. Y., Yap, C. W., et al. (2003). Drug adverse reaction
target database (dart). Drug safety, 26(10), 685–690.
[30]Chen, X., Ji, Z. L., and Chen, Y. Z. (2002). Ttd: therapeutic target
database. Nucleic acids research, 30(1), 412–415.
[31]Belleau, F., Nolin, M.-A., Tourigny, N., et al. (2008). Bio2rdf:
towards a mashup to build bioinformatics knowledge systems. Journal
of biomedical informatics, 41(5), 706–716.
[32]Simpson, S. E., Madigan, D., Zorych, I., et al. (2013). Multiple
self-controlled case series for large-scale longitudinal observational
databases. Biometrics, 69(4), 893–902.
[33]Huynh, T., He, Y., Willis, A., et al. (2016). Adverse drug reaction
classification with deep neural networks. In Proceedings of COLING.
Coling, COLING.
[34]Lee, K., Qadir, A., Hasan, S. A., et al. (2017). Adverse drug event
detection in tweets with semi-supervised convolutional neural networks.
In Proceedings of the 26th International Conference on World Wide Web,
pages 705–714. International World Wide Web Conferences Steering
Committee, WWW.
[35]Emadzadeh, E., Sarker, A., Nikfarjam, A., and Gonzalez, G.
(2017). Hybrid semantic analysis for mapping adverse drug reaction
mentions in tweets to medical terminology. In AMIA Annual Symposium
Proceedings, volume 2017, page 679. American Medical Informatics
Association, PubMed Central.
[36]Ring, J. and Brockow, K. (2002). Adverse drug reactions: mechanisms
and assessment. European surgical research, 34(1-2), 170–175.
11
[37]Testa, B. and Kier, L. B. (1991). The concept of molecular structure
in structure–activity relationship studies and drug design. Medicinal
research reviews, 11(1), 35–48.
[38]Todeschini, R. and Consonni, V. (2008). Handbook of molecular
descriptors, volume 11. John Wiley & Sons.
[39]Grisoni, F., Ballabio, D., Todeschini, R., et al. (2018). Molecular
descriptors for structure–activity applications: A hands-on approach. In
Computational Toxicology, pages 3–53. Springer.
[40]Steinbeck, C., Han, Y., Kuhn, S., et al. (2003). The chemistry
development kit (cdk): An open-source java library for chemo-and
bioinformatics. Journal of chemical information and computer sciences,
43(2), 493–500.
[41]Daylight Chemica Information System, Inc (2018). Daylight theory:
Fingerprint.
http://www.daylight.com/dayhtml/doc/
theory/theory.finger.html (10 Sep 2019, date last accessed).
[42]Hall, L. H. and Kier, L. B. (1995). Electrotopological state indices for
atom types: a novel combination of electronic, topological, and valence
state information. Journal of Chemical Information and Computer
Sciences, 35(6), 1039–1045.
[43]Klekota, J. and Roth, F. P. (2008). Chemical substructures that enrich
for biological activity. Bioinformatics, 24(21), 2518–2525.
[44]Durant, J. L., Leland, B. A., Henry, D. R., and Nourse, J. G. (2002).
Reoptimization of mdl keys for use in drug discovery. Journal of chemical
information and computer sciences, 42(6), 1273–1280.
[45]Bolton, E. E., Kim, S., and Bryant, S. H. (2011). Pubchem3d:
conformer generation. Journal of cheminformatics, 3(1), 4.
[46]Openeye scientific software (2018). OMEGA. https://www.
eyesopen.com/omega (10 Nov 2018, date last accessed).
[47]Wermuth, C. G. (2011). The practice of medicinal chemistry.
Academic Press.
[48]Goodford, P. J. (1985). A computational procedure for determining
energetically favorable binding sites on biologically important
macromolecules. Journal of medicinal chemistry, 28(7), 849–857.
[49]Crivori, P., Cruciani, G., Carrupt, P. A., et al. (2000). Predicting bloodbrain barrier permeation from three-dimensional molecular structure.
Journal of medicinal chemistry, 43(11), 2204–2216.
[50]Kubinyi, H. (1998). Comparative molecular field analysis (comfa).
The encyclopedia of computational chemistry, 1, 448–460.
[51]Cruciani, G., Carosati, E., De Boeck, B., et al. (2005). Metasite:
understanding metabolism in human cytochromes from the perspective
of the chemist. Journal of medicinal chemistry, 48(22), 6970–6979.
[52]Young, R. C., Mitchell, R. C., Brown, T. H., et al. (1988).
Development of a new physicochemical model for brain penetration and
its application to the design of centrally acting h2 receptor histamine
antagonists. Journal of medicinal chemistry, 31(3), 656–671.
[53]Testa, B., Caron, G., Crivori, P., et al. (2000). Lipophilicity and related
molecular properties as determinants of pharmacokinetic behaviour.
CHIMIA International Journal for Chemistry, 54(11), 672–677.
[54]van de Waterbeemd, H. and Kansy, M. (1992). Hydrogen-bonding
capacity and brain penetration. CHIMIA International Journal for
Chemistry, 46(7-8), 299–303.
[55]Lipinski, C. A., Lombardo, F., Dominy, B. W., et al. (1997).
Experimental and computational approaches to estimate solubility and
permeability in drug discovery and development settings. Advanced drug
delivery reviews, 23(1-3), 3–25.
[56]WHO Collaborating Centre for Drug Statistics Methodology
(2019).
Guidelines for atc classification and ddd assignment.
https://www.whocc.no/filearchive/publications/
2019_guidelines_web.pdf, (10 Sep 2019, date last accessed).
[57]Yamanishi, Y., Pauwels, E., and Kotera, M. (2012). Drug side-effect
prediction based on the integration of chemical and biological spaces.
Journal of chemical information and modeling, 52(12), 3284–3292.
A Self-archived copy in
Kyoto University Research Information Repository
https://repository.kulib.kyoto-u.ac.jp
“main” — 2019/11/18 — 13:41 — page 12 — #12
12
[58]Montastruc, J.-L., Sommet, A., Bagheri, H., and Lapeyre-Mestre,
M. (2011). Benefits and strengths of the disproportionality analysis for
identification of adverse drug reactions in a pharmacovigilance database.
British journal of clinical pharmacology, 72(6), 905–908.
[59]Agresti, A. (1992). A survey of exact inference for contingency tables.
Statistical science, 7(1), 131–153.
[60]Kuhn, M., Campillos, M., Letunic, I., et al. (2010). A side effect
resource to capture phenotypic effects of drugs. Molecular systems
biology, 6(1), 343.
[61]Yang, F., Yu, X., and Karypis, G. (2014). Signaling adverse drug
reactions with novel feature-based similarity model. In Bioinformatics
and Biomedicine (BIBM), 2014 IEEE International Conference on, pages
593–596. IEEE, IEEE.
[62]Chen, A. W. (2018). Predicting adverse drug reaction outcomes with
machine learning. International Journal Of Community Medicine And
Public Health, 5(3), 901–904.
[63]Huba, G., Wingard, J. A., and Bentler, P. M. (1981). A comparison
of two latent variable causal models for adolescent drug use. Journal of
Personality and Social Psychology, 40(1), 180.
[64]Zhang, W., Liu, F., Luo, L., et al. (2015). Predicting drug side effects
by multi-label learning and ensemble learning. BMC bioinformatics,
16(1), 365.
[65]Muñoz, E., Nováˇcek, V., and Vandenbussche, P.-Y. (2017).
Facilitating prediction of adverse drug reactions by using knowledge
graphs and multi-label learning models. Briefings in bioinformatics,
20(1), 190–202.
[66]Cao, D., Xiao, N., Li, Y., et al. (2015). Integrating multiple
evidence sources to predict adverse drug reactions based on a systems
pharmacology model. CPT: pharmacometrics & systems pharmacology,
4(9), 498–506.
[67]Pauwels, E., Stoven, V., and Yamanishi, Y. (2011). Predicting
drug side-effect profiles: a chemical fragment-based approach. BMC
bioinformatics, 12(1), 169.
[68]Muñoz, E., Nováˇcek, V., and Vandenbussche, P.-Y. (2016). Using drug
similarities for discovery of possible adverse reactions. In AMIA Annual
Symposium Proceedings, volume 2016, page 924. American Medical
Informatics Association.
[69]Zhang, W., Chen, Y., Tu, S., et al. (2016). Drug side effect prediction
through linear neighborhoods and multiple data source integration. In
2016 IEEE international conference on bioinformatics and biomedicine
(BIBM), pages 427–434. IEEE.
[70]Jahid, M. J. and Ruan, J. (2013). An ensemble approach for drug
side effect prediction. In Bioinformatics and Biomedicine (BIBM), 2013
IEEE International Conference on, volume 2013, pages 440–445. IEEE,
IEEE.
[71]Cami, A., Arnold, A., Manzi, S., and Reis, B. (2011). Predicting
adverse drug events using pharmacological network models. Science
translational medicine, 3(114), 114ra127–114ra127.
[72]Lin, J., Kuang, Q., Li, Y., and et al. (2013). Prediction of adverse drug
reactions by a network based external link prediction method. Analytical
Nguyen et al.
Methods, 5(21), 6120–6127.
[73]Davazdahemami, B. and Delen, D. (2018). A chronological
pharmacovigilance network analytics approach for predicting adverse
drug events. Journal of the American Medical Informatics Association,
25(10), 1311–1321.
[74]Tong, H., Faloutsos, C., and Pan, J.-Y. (2006). Fast random walk with
restart and its applications. In Sixth International Conference on Data
Mining (ICDM’06), pages 613–622. IEEE, IEEE.
[75]Rahmani, H., Weiss, G., Méndez-Lucio, O., et al. (2016). Arwar: A
network approach for predicting adverse drug reactions. Computers in
biology and medicine, 68, 101–108.
[76]Poleksic, A. and Xie, L. (2018). Predicting serious rare adverse
reactions of novel chemicals. Bioinformatics, 1, 8.
[77]Zitnik, M., Agrawal, M., and Leskovec, J. (2018). Modeling
polypharmacy side effects with graph convolutional networks.
Bioinformatics, 34(13), i457–i466.
[78]Wang, C.-S., Lin, P.-J., Cheng, C.-L., et al. (2019). Detecting potential
adverse drug reactions using a deep neural network model. Journal of
medical Internet research, 21(2), e11016.
[79]Dey, S., Luo, H., Fokoue, A., et al. (2018). Predicting adverse
drug reactions through interpretable deep learning framework. BMC
bioinformatics, 19(21), 476.
[80]Dimitri, G. M. and Lió, P. (2017). Drugclust: a machine learning
approach for drugs side effects prediction. Computational biology and
chemistry, 68, 204–210.
[81]Xiao, C., Zhang, P., Chaowalitwongse, W. A., et al. (2017). Adverse
drug reaction prediction with symbolic latent dirichlet allocation.
In Proceedings of the Thirty-First AAAI Conference on Artificial
Intelligence. AAAI Press.
[82]Shaked, I., Oberhardt, M. A., Atias, N., et al. (2016). Metabolic
network prediction of drug side effects. Cell systems, 2(3), 209–213.
[83]Mahadevan, R. and Schilling, C. (2003). The effects of alternate
optimal solutions in constraint-based genome-scale metabolic models.
Metabolic engineering, 5(4), 264–276.
[84]Wallach, I., Jaitly, N., and Lilien, R. (2010). A structure-based
approach for mapping adverse drug reactions to the perturbation of
underlying biological pathways. PloS one, 5(8), e12063.
[85]Zheng, H., Wang, H., Xu, H., et al. (2014). Linking biochemical
pathways and networks to adverse drug reactions. IEEE transactions on
nanobioscience, 13(2), 131–137.
[86]Chen, X., Liu, X., Jia, X., et al. (2013). Network characteristic
analysis of adr-related proteins and identification of adr-adr associations.
Scientific reports, 3, 1744.
[87]Jiang, Y., Li, Y., Kuang, Q., et al. (2014). Predicting putative adverse
drug reaction related proteins based on network topological properties.
Analytical Methods, 6(8), 2692–2698.
[88]Wang, J., Li, Z.-x., Qiu, C.-x., et al. (2011). The relationship between
rational drug design and drug side effects. Briefings in bioinformatics,
13(3), 377–382.
...
論文の公開元へ
